Alexander Rotenberg
Neurology with Special Qualifications in Child Neurology · Boston, MANPI 1154348043
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $32,463 of the $34,411 with a category attached, or 94.3%. 10 manufacturers reported payments, led by F. Hoffmann-la Roche AG at 40.2% of the total. Reporting peaked in 2024 at $16,589 and has fallen 93.6% since, to $1,068 in 2025. Among neurology with special qualifications in child neurology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 38 payments — averaging $905.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$14K
- Takeda Pharmaceuticals U.S.A., Inc.$9K
- Trevena, Inc.$5K
- AbbVie$3K
- Alkermes, Inc.$3K
- Biomarin Pharmaceutical Inc.$172
- plus $367 from 4 others
Across 30 payments — averaging $27,845 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$280K
- Takeda Pharmaceuticals U.S.A., Inc.$267K
- Genentech, Inc.$263K
- Biomarin Pharmaceutical Inc.$25K
What the payments were for
- Consulting fees$32,46394%
- Travel & lodging$9173%
- Food & beverage$1,0303%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 7 | $13,835 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $9,056 |
| Trevena, Inc. | 2 | $4,981 |
| AbbVie | 3 | $3,100 |
| Alkermes, Inc. | 1 | $2,900 |
| Biomarin Pharmaceutical Inc. | 3 | $172 |
| SK Life Science, Inc. | 2 | $148 |
| UCB, Inc. | 4 | $124 |
| Vertex | 3 | $65 |
| Immedica Pharma US, Inc. | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$5,615
- Olinvyk$4,917
- XCOPRI$125
How this compares
$34,411 in reported general payments places this provider in the 90th percentile of 101 neurology with special qualifications in child neurology providers in Massachusetts.
See all neurology with special qualifications in child neurology providers in Massachusetts →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZtalmyGanaxolone | 12 | $310,786 |
| EpidiolexCannabidiol (Cbd) | 11 | $56,853 |
| Rufinamide | 17 | $18,865 |
| XcopriCenobamate | 13 | $15,460 |
| Felbamate | 13 | $2,821 |
| Divalproex Sodium | 13 | $586 |
| Lamotrigine | 17 | $432 |
| Clonazepam | 25 | $348 |
| Clobazam | 11 | $318 |
| Oxcarbazepine | 18 | $256 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $148 | $15,46013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 101 neurology with special qualifications in child neurology providers in Massachusetts.
Other neurology with special qualifications in child neurology in Boston
- Elizabeth ThieleBoston$278K
- Jurriaan PetersBoston$265K
- Basil DarrasBoston$253K
- Kiran MaskiBoston$105K
- Phillip PearlBoston$50K
- Irina AnselmBoston$30K
- Nicole UllrichBoston$26K
- David LiebermanBoston$19K
- Robert StoweBoston$9K
- Siddharth SrivastavaBoston$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.